Pleading guilty to marketing Depakote for behavioral problems in dementia patients, a purpose for which the drug was not approved, a federal judge has assessed Abbott pharmaceuticals a criminal fine of $500 million, forfeiture of $198.5 million, and a payment of $1.5 million to Virginia’s Medicaid Fraud Control Unit.